
Combined Radio- And Immunotherapy Of Aggressive NhlAward last edited on: 3/4/14
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$1,997,013Award Phase
2Solicitation Topic Code
-----Principal Investigator
William A WegenerCompany Information
ImmunoMedics Inc
300 The American Road
Morris Plains, NJ 07950
Morris Plains, NJ 07950
(973) 605-8200 |
info@immunomedics.com |
www.immunomedics.com |
Location: Single
Congr. District: 11
County: Morris
Congr. District: 11
County: Morris
Phase I
Contract Number: 1R44CA139668-01A1Start Date: 00/00/00 Completed: 00/00/00
Phase I year
2009Phase I Amount
$859,792Public Health Relevance:
This project will assess the safety and efficacy of a new combination radioimmunotherapy and immunotherapy treatment paradigm that will be applied to aggressive non-Hodgkin lymphoma. The treatment consists of a fractionated 90Y-DOTA-humanized anti-CD22 IgG (epratuzumab) given in combination with a humanized anti-CD20 IgG (veltuzumab), given in conjunction with the radioimmunotherapy, as well as a consolidation follow-up.
Public Health Relevance Statement:
This project will assess the safety and efficacy of a new combination radioimmunotherapy and immunotherapy treatment paradigm that will be applied to aggressive non-Hodgkin lymphoma. The treatment consists of a fractionated 90Y-DOTA-humanized anti-CD22 IgG (epratuzumab) given in combination with a humanized anti-CD20 IgG (veltuzumab), given in conjunction with the radioimmunotherapy, as well as a consolidation follow-up.
Project Terms:
ATGN; Active Follow-up; Aged 65 and Over; Antibodies; Antibody Formation; Antibody Production; Antibody Response; Antibody Therapy; Antigens; Arm; B blood cells; B lymphoma; B-Cell Lymphomas; B-Cell Non-Hodgkin's Lymphoma; B-Cell NonHodgkins Lymphoma; B-Cells; B-Lymphocytes; Biodistribution; Biological; Bp35; Bursa-Dependent Lymphocytes; Bursa-Equivalent Lymphocyte; C2B8 Monoclonal Antibody; CD20; Cancer Center; Cancer, Oncology; Cancers; Cell Count; Cell Number; Cells; Chemical Fractionation; Clinical; Clinical Investigator; Clinical Research; Clinical Study; Clinical Trials; Clinical Trials, Phase II; Clinical Trials, Unspecified; Combined Modality Therapy; Controlled Study; Cytofluorometry, Flow; DLBCL; Data; Diffuse Large B-Cell Lymphoma; Diffuse non-Hodgkin's lymphoma, large cell; Disease; Disease Resistance; Disorder; Doctor of Philosophy; Dose; Drug Kinetics; Elderly; Elderly, over 65; Ensure; Epratuzumab; Epratuzumab (hLL2); FRACN; Flow Cytofluorometries; Flow Cytometry; Flow Microfluorimetry; Fractionation; Fractionation Radiotherapy; Gamma Camera Imaging; Gamma Globulin, 7S; Germinoblastoma; Goals; High Dose Chemotherapy; Humanized Anti-CD22 Monoclonal Antibody IgG1; ITX; Ibritumomab Tiuxetan; IgG; Image; Immunoglobulin G; Immunologically Directed Therapy; Immunoradiotherapy; Immunotherapeutic agent; Immunotherapy; Immunotherapy, Cancer, Radioisotope; Infusion; Infusion procedures; Injection of therapeutic agent; Injections; Investigators; Journals; Label; Leu-16; LymphoCide; Lymphoma; Lymphoma (Hodgkin's and Non-Hodgkin's); Lymphoma, Malignant; Lymphoma, Non-Hodgkin's; Lymphoma, Nonhodgkins; MS4A1; MS4A1 gene; MS4A2; Magazine; Malignant Neoplasms; Malignant Tumor; Mammals, Mice; Maximal Tolerated Dose; Maximally Tolerated Dose; Maximum Tolerated Dose; Medical; Mice; Microfluorometry, Flow; Moab, Clinical Treatment; Monitor; Monoclonal Antibodies; Multimodal Therapy; Multimodal Treatment; Multimodality Treatment; Murine; Mus; Myron; Myron (drug combination); New Agents; Non-Hodgkin's Lymphoma; Patients; Peripheral; Ph.D.; PhD; Pharmacokinetics; Phase; Phase 2 Clinical Trials; Phase II Clinical Trials; Position; Positioning Attribute; Principal Investigator; Progenitor Cell Transplantation; Protocols, Treatment; Publications; RGM; Radiation; Radio; Radio Conjugates; Radioconjugate; Radioimmunotherapy; Radionuclide Imaging; Refractory; Regimen; Relapse; Research Personnel; Researchers; Residual Tumors; Resistance; Resistance, Disease; Resort; Reticulolymphosarcoma; Retreatment; Rituximab (C2B8 Antibody); Roswell Park Cancer Institute; SBIR; SBIRS (R43/44); Safety; Salvage Therapy; Salvage-Tx; Sarcoma, Germinoblastic; Scanning, Radioisotope; Scheme; Scientific Publication; Scintigraphy; Secondary to; Small Business Innovation Research; Small Business Innovation Research Grant; Stem Cell Transplantation; Stem cell transplant; Therapeutic; Translating; Translatings; Transplantation; Treatment Protocols; Treatment Regimen; Treatment Schedule; Tumors, Residual; Upper arm; advanced age; alternative treatment; antibody biosynthesis; base; chemotherapy; clinical investigation; combination therapy; combined modality treatment; combined treatment; design; designing; disease/disorder; elders; experience; flow cytophotometry; follow-up; geriatric; hLL2; hLL2 agent; imaging; immune therapy; immunogen; immunoglobulin biosynthesis; immunologic preparation; immunotherapeutics; improved; language translation; large cell Diffuse non-Hodgkin's lymphoma; late life; later life; malignancy; meetings; multimodality therapy; neoplasm/cancer; non-Hodgkin's lymphoma; non-Hodgkins disease; non-Hodgkins lymphoma; novel; older adult; older person; oncology; phase 2 study; phase 2 trial; phase II trial; pre-clinical; preclinical; preclinical study; protocol, phase II; public health relevance; radionuclide imaging/scanning; radionuclide scanning; ray (radiation); residual disease; resistance to disease; resistant; resistant disease; resistant to disease; response; rituximab; senior citizen; standard care; study, phase II; transplant; treatment response; tumor; uptake
Phase II
Contract Number: 4R44CA139668-02Start Date: 9/21/09 Completed: 7/31/14
Phase II year
2013Phase II Amount
$1,137,221Public Health Relevance:
This project will assess the safety and efficacy of a new combination radioimmunotherapy and immunotherapy treatment paradigm that will be applied to aggressive non-Hodgkin lymphoma. The treatment consists of a fractionated 90Y-DOTA-humanized anti-CD22 IgG (epratuzumab) given in combination with a humanized anti-CD20 IgG (veltuzumab), given in conjunction with the radioimmunotherapy, as well as a consolidation follow-up.
Public Health Relevance Statement:
This project will assess the safety and efficacy of a new combination radioimmunotherapy and immunotherapy treatment paradigm that will be applied to aggressive non-Hodgkin lymphoma. The treatment consists of a fractionated 90Y-DOTA-humanized anti-CD22 IgG (epratuzumab) given in combination with a humanized anti-CD20 IgG (veltuzumab), given in conjunction with the radioimmunotherapy, as well as a consolidation follow-up.
Project Terms:
alternative treatment; Antibodies; Antibody Formation; Antibody Therapy; Antigens; arm; B-Cell Lymphomas; B-Lymphocytes; base; Biodistribution; Biological; Cancer Center; CD22 gene; Cell Count; Cells; chemotherapy; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Combined Modality Therapy; Controlled Study; Data; design; Disease; Disease Resistance; Doctor of Philosophy; Dose; Drug Kinetics; Elderly; Ensure; Epratuzumab; experience; Flow Cytometry; follow-up; Fractionation; Goals; Health; High Dose Chemotherapy; Ibritumomab Tiuxetan; Image; Immunoglobulin G; Immunotherapeutic agent; Immunotherapy; improved; Infusion procedures; Injection of therapeutic agent; Journals; Label; large cell Diffuse non-Hodgkin's lymphoma; Lymphoma; Malignant Neoplasms; Maximum Tolerated Dose; Medical; meetings; Monitor; Monoclonal Antibodies; MS4A1 gene; Mus; Myron (drug combination); New Agents; Non-Hodgkin's Lymphoma; novel; oncology; Patients; Peripheral; Phase; Phase II Clinical Trials; Positioning Attribute; pre-clinical; preclinical study; Principal Investigator; Publications; Radiation; Radiation therapy; Radioconjugate; Radioimmunotherapy; Radionuclide Imaging; Refractory; Regimen; Relapse; Research Personnel; Residual Tumors; Resistance; Resort; response; Retreatment; rituximab; Roswell Park Cancer Institute; Safety; Salvage Therapy; Scheme; Secondary to; Small Business Innovation Research Grant; standard care; Stem cell transplant; Therapeutic; Translating; Transplantation; treatment duration; Treatment Protocols; treatment response; tumor; uptake